Dobutamine Echocardiography After Cardiac Arrest
Overview
Tab Title Description
Study type
ObservationalDescribes the nature of a clinical study. Types include:
- Observational study — observes people and measures outcomes without affecting results.
- Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
- Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
Study IDs
Site IRB
- Rochester, Minnesota: 17-003520
Sponsor Protocol Number: 17-003520
About this study
This purpose of this study is to evaluate the feasibility and safety of dobutamine stress echocardiography in patients who suffered an OHCA, as a way to predict recovery of heart function.
Participation eligibility
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.
Inclusion Criteria:
- Adult (age ≥ 18 years).
- Resuscitated from non-traumatic cardiac arrest (including any arrest rhythm or non-traumatic etiology, including in-hospital and out-of-hospital cardiac arrest) admitted to Mary Brigh 4 D/E CICU.
- Sinus rhythm at the time of enrollment OR underlying atrial fibrillation with a paced rhythm present.
Exclusion Criteria:
- Atrial fibrillation (or other non-sinus rhythm) at the time of enrollment unless a paced rhythm is present.
- Mechanical circulatory support (including intra-aortic balloon pump).
- DNR status.
- Inadequate imaging windows for satisfactory TTE data acquisition.
- Need for inotropic support (any dose of dobutamine, epinephrine, dopamine) or high-dose vasopressors (norepinephrine >0.1 mcg/kg/min or equivalent) at baseline.
- Pregnant women.
- Prisoners
- Secondary exclusion criteria ONLY apply to the DSE sub-study:
- Atrial or ventricular arrhythmias requiring ongoing intravenous antiarrhythmic drug therapy;
- Unrevascularized severe CAD or concern for ongoing myocardial ischemia;
- Clinical judgement by the treating physician that low-dose dobutamine would be harmful;
- Known sensitivity or allergy to dobutamine.
Participating Mayo Clinic locations
Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.
| Mayo Clinic Location |
Status |
|
Rochester, Minn.
Mayo Clinic principal investigator Jacob Jentzer, M.D. |
Closed for enrollment |
|
More information
Publications
Publications are currently not available